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Abstract
Background: Severe aortic valve stenosis inhibits renal perfusion, thereby potentially worsening renal 
function, in particular in elderly patients most often assigned to transcatheter aortic valve implantation 
(TAVI). Pre-TAVI diagnostics and the procedure itself may adversely impact renal function, however 
renal perfusion and function may also improve post-procedure. This study aimed to clarify the impact 
of TAVI planning and procedure on kidney function
Methods: In this retrospective study, kidney function of patients who underwent transfemoral TAVI 
at a tertiary university hospital between 2016 and 2019 was analyzed. The present study investigated 
kidney function at baseline, after computed tomography (CT) was performed for evaluation of TAVI, 
after TAVI, at discharge and at follow-up. 
Results: Among 366 patients, the prevalence of acute kidney injury (AKI) was 14.5% after TAVI. In-
dependent predictors of AKI were arterial hypertension, baseline creatinine, AKI post CT and coronary 
intervention during pre-procedural diagnostics. At discharge and follow-up, 2.1% and 3.4%, respec-
tively had sustained relevant impairment of kidney function (defined as creatinine/baseline creatinine 
> 1.5 or renal replacement therapy). Patients with known chronic kidney disease showed no higher 
rates of short- and long-term impairment, but higher rates of improvement of renal function after TAVI. 
Conclusions: In most cases TAVI does not worsen renal function. A sustained impairment after TAVI 
was found in only a few cases. This was independent of reduced baseline kidney function. Transfemoral 
TAVI can thus be planned and performed even in patients with higher stages of chronic kidney disease. 
(Cardiol J)
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Chronic kidney disease (CKD) is common and 
associated with an increased risk of cardiovascular 
events [1]. Besides coronary artery disease, valvular 
heart disease also affects survival in these patients. 
Prevalence of aortic valve stenosis is higher and is 
associated with significantly higher mortality [2]. 
Transcatheter aortic valve implantation (TAVI) 
is an established minimally invasive method for 
treating patients with severe aortic stenosis [3]. 
While patients with CKD are at increased risk 
for short- and long-term mortality among high-
-surgical-risk patients undergoing TAVI, there 
is no association between CKD and mortality in 
low- to intermediate-risk patients [4]. Publications 
analyzing the risk of acute kidney injury (AKI) after 
TAVI are also inconclusive [5–9]. Since publications 
focus on AKI after TAVI, little is known about the 
impact of aortic valve stenosis, the total workflow 
of pre-procedural TAVI diagnostics and the proce-
dure itself on short- and long-term renal function. 
On the one hand, the need for contrast agent or 
complications during TAVI procedure may lead to 
impairment of kidney function; on the other hand, 
hemodynamic improvement of kidney perfusion 
after TAVI may even improve renal function.
Apart from the periinterventional risk, pre-
procedural diagnostics are also under discussion as 
possibly impairing kidney function: First, contrast 
enhanced computed tomography (CT) with contrast 
agent application is used to evaluate anatomy of the 
aortic valve and aorta, providing valuable information 
for pre-procedural planning [10]. Second, coronary 
angiography is indicated for the assessment of coro-
nary artery disease [11]. Interestingly, there is little 
literature analyzing CKD and AKI after CT prior to 
TAVI [12], while no data exists on the impact of AKI 
on long-term renal function after TAVI. However, it 
is a frequent clinical question whether a TAVI can 
safely be planned and performed in patients at risk 
for impaired renal function.
In order to clarify the impact of TAVI on renal 
function we investigated acute and chronic renal 
failure over the complete TAVI process, including 
pre-procedural diagnostics and the intervention 
itself. Furthermore, risk factors for the develop-
ment of renal failure are identified.
Methods
Study population
Medical records of patients who underwent 
CT for evaluation of TAVI, and who underwent 
transfemoral TAVI (TF-TAVI) at a tertiary uni-
versity hospital between 2016 and 2019 were 
retrospectively analyzed. Only patients with 
severe aortic valve stenosis were included for 
further analyses. 
The indication for TAVI treatment was made 
by an interdisciplinary heart team consisting of 
cardiologists, heart surgeons, and anesthesiolo-
gists. Analysis was blinded to patient identity and 
was covered by an ethics approval committee 
(Ethics Committee of Albert-Ludwigs University 
of Freiburg, file number EK 29/11). 
Pre-procedural screening and intervention 
All contrast-enhanced CT examinations were 
performed on a second-generation dual-source 
CT scanner (DSCT, Somatom Definition Flash, 
Siemens Healthineers) according to current 
guidelines. A scout view of thorax and abdomen 
was obtained to plan data acquisitions. Coronary 
angiography was routinely performed before 
TAVI. If TAVI was the only possible therapeutic 
intervention, coronary angiography could be 
performed during the TAVI procedure. Percutane-
ous coronary intervention (PCI) was performed, 
if necessary based on current guidelines of the 
European Society of Cardiology. For TAVI, valvu-
loplasty was left to the discretion of the treating 
physician. Several types of valves were individu-
ally selected (Edwards Sapien 3/XT, Medtronic 
Evolute R/Pro, DirectFlow, Symetis Acurate 
neo) and implanted by an experienced team of 
interventional cardiologists, cardiac surgeons, 
and anesthesiologists.
Renal function
Baseline renal function was calculated as 
estimated glomerular filtration rate (eGFR) of 
mean creatinine levels before the first application 
of contrast agent using the Modification of Diet in 
Renal Disease (MDRD) GFR equation. An eGFR 
< 60 mL/min (CKD stage ≥ III Kidney Disease: 
Improving Global Outcomes [KDIGO]) was con-
sidered as relevant CKD. AKI was defined as 
increase of serum creatinine of ≥ 0.3 mg/dL or to 
≥ 1.5 times baseline, according to the acute kidney 
injury network criteria [13]. Creatinine levels were 
measured at the discretion of the treating physician 
and considered to be associated with the procedure 
if the increase occurred within 7 days. If TAVI was 
performed earlier than 7 days after the last contrast 
agent application, creatinine levels were distrib-
uted manually to TAVI or pre-TAVI diagnostics, 




All patients who underwent transfemoral TAVI 
were identified. By manual case by case review, 
patients were excluded if they met one or more of 
the exclusion criteria, which were chronic renal 
replacement therapy (RRT), shock or cardiopulmo-
nary resuscitation in short period to diagnostics/ 
/TAVI, and conversion to surgical valve replace-
ment. Since patients with transplanted kidneys 
were very rare (2/368), we decided to exclude this 
patient collective as well. All outcome variables 
were evaluated by manual search of medical and 
patient records.
Statistical analysis
For data analysis, SPSS (version 26, IBM 
Statistics) and Prism (version 5, GraphPad) were 
employed. For statistical analysis, the students 
t-test, the Fisher exact test and the c2 test 
were used when appropriate, and a p value of 
< 0.05 was considered statistically significant. Mul-
tivariate regression binary analysis was performed 
for predictors of AKI and impairment of kidney 
function (p < 0.05) to check for interactions and to 
estimate the magnitude of the predictor. A possible 
collinearity may be present concerning AKI post 
CT and AKI post TAVI. Results are given as odds 
ratio ([OR], 95% confidence interval [CI]). Again, 
a p-value of < 0.05 was considered statistically 
significant. Data are given as number (%), mean ± 
standard deviation or OR with 95% CI if not stated 
otherwise. For missing variables in multivariate 
binary analysis, multiple imputation was applied. 
All analyses were exploratory in nature. As a re-
sult, p-values and 95% CIs were not corrected for 
multiple comparisons and inferences drawn from 
them may not be reproducible. 
Results
Patient characteristics
Within the observed time period, TF-TAVI 
was performed in 394 patients. A total of 28 pa-
tients were excluded from analysis (15 on chronic 
RRT; 2 with transplanted kidneys; 5 with shock 
or cardiopulmonary rescuscitation in short period 
to diagnostics/TAVI, 5 with conversion to surgical 
valve replacement, 1 patient with missing data after 
TAVI). Therefore, 366 patients could be evaluated. 
Of these, 37 patients had no creatinine measure-
ments after CT, mainly because of early hospital 
discharge (Suppl. Fig. 1). 
Mean age was 81.1 ± 5.9 years, 200 (54.6%) 
patients were female. Baseline creatinine was 1.16 
± 0.44 mg/dL. A total of 176 (48.1%) patients had 
relevant CKD with an eGFR < 60 mL/min (Table 1). 
Renal function during TAVI diagnostics, 
TAVI and after TAVI
Creatinine levels were analyzed during the 
complete workflow including baseline-creatinine, 
creatinine after CT, before/after TAVI, at discharge, 
and in follow up examinations (161 ± 87 days). In 
relation to baseline creatinine, the mean creatinine 
after CT minimally deteriorated (+0.004 ± 0.230 
mg/dL) and peaked after TAVI (+0.101 ± 0.455 mg/ 
/dL). At discharge, creatinine marginally improved 
(–0.03 ± 0.358 mg/dL) in all patients. The group 
with higher CKD stages showed a significant im-
provement in renal function compared to patients 
with lower CKD stages (–0.121 ± 0.346 mg/dL 
vs. +0.042 ± 0.352 mg/dL, p < 0.001). Analyzing 
the long-term data at follow up (n = 183, 1 patient 
with RRT, 88 with initial CKD ≥ III), creatinine-
-levels in relation to baseline-creatinine increased 
slightly in both CKD ≥ III and CKD ≤ II patients 
(+0.014 ± 0.310 mg/dL vs. +0.088 ± 0.152 mg/ 
/dL, p = 0.039), but were under the threshold for 
AKI of +0.3 mg/dL increase of creatinine (Fig. 1A). 
Levels of eGFR were stable throughout the whole 
procedure (Fig. 1B).
Patients developing AKI are at risk for long-
-term kidney failure. Therefore, we extracted 
patients with AKI post TAVI (n = 53, 14.5%). 
Naturally, patients with AKI post TAVI showed 
their highest creatinine levels after TAVI (in total 
2.28 ± 1.06 mg/dL vs. 1.09 ± 0.38 mg/dL; in rela-
tion to baseline creatinine +0.80 ± 0.81 mg/dL vs. 
–0.02 ± 0.19 mg/dL). Creatinine levels improved 
and showed slightly impaired levels at discharge 
in relation to baseline creatinine (+0.18 ± 0.78 
mg/dL vs. –0.07 ± 0.20 mg/dL), with stable levels 
on follow up examinations (‘n’ at follow up = 183) 
(Fig. 1C). 
Risk factors for AKI after CT 
In order to identify patients at risk for AKI 
during TAVI planning, creatinine levels and risk 
factors after CT were analyzed. Of all 329 patients 
with documented creatinine levels after CT, 22 
(6.7%) patients had AKI after CT. All patients had 
KDIGO stage I of AKI and no RRT was necessary 
after CT. CKD was more present in patients with 
AKI (77.3% vs. 22.7%, p = 0.006). No correlation 
was identified between amount of contrast agent 
and AKI (AKI 113.7 ± 4.4 mL vs. no AKI 113.2 ± 
± 4.2 mL; p = 0.586). No independent predictors 
of AKI post CT were identified with a multivariate 
www.cardiologyjournal.org 3
Markus Jäckel et al., Kidney function after TAVI
Table 1. Baseline characteristics of all patients and all patients with or without acute kidney injury (AKI) 
after transcatheter aortic valve implantation (TAVI). 
All patients  
(n = 366)





Age 82.1 ± 5.9 81.8 ± 5.9 84.1  ±5.4 0.007
Female 200 (54.6%) 169 (54.0%) 31 (58.5%) 0.543
Weight [kg] 73.2 ± 15.3 73.8 ± 15.6 70.2 ± 13.0 0.118
Comorbidities
STS-Score [%] 7.4 ± 4.6 7.0 ± 4.5 9.8 ± 4.3 0.001
NYHA class 2.3 ± 1.2 2.3 ± 1.2 2.5 ± 1.2 0.192
CCS class 0.9 ± 1.3 0.8 ± 1.2 1.2 ± 1.4 0.095
Atherosclerosis 26 (73%) 224 (71.6%) 43 (81.1%) 0.147
Atrial fibrillation 156 (42.6%) 129 (41.2%) 27 (50.9%) 0.185
Hypertension 300 (82%) 250 (79.9%) 50 (94.3%) 0.011
Diabetes mellitus 107 (29.2%) 94 (30%) 13 (24.5%) 0.415
Smoking 74 (20.2%) 65 (20.8%) 9 (17%) 0.526
Syncope 62 (16.9%) 53 (17.2%) 8 (17%) 0.976
History of stroke/cerebral bleeding 56 (15.3%) 48 (15.3%) 8 (15.1%) 0.964
Pulmonary disease 75 (20.5%) 65 (20.8%) 10 (18.9%) 0.751
Malignancy 110 (30.1%) 90 (28.8%) 20 (37.7%) 0.187
Alcohol abuse 9 (2.5%) 8 (2.6%) 1 (1.9%) 1.000
ACEI/sartan 263 (71.9%) 220 (73.8%) 43 (81.1%) 0.258
Metformin 5 (13.9%) 47 (15%) 4 (7.5%) 0.147
Baseline characteristics
Mean AV gradient [mmHg] 42.2 ± 13.9 42.5 ± 13.8 40.1 ± 14.8 0.250
AV opening area [cm2] 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.735
Mitral valve insufficiency 1.3 ± 0.6 1.2 ± 0.5 1.4 ± 0.6 0.157
Ejection fraction [%] 50.8 ± 10.3 51.0 ± 10.0 49.6 ± 12.1 0.357
Baseline-creatinine [mg/dL] 1.16 ± 0.44 1.10 ± 0.39 1.48 ± 0.55 0.001
eGFR [mL/min] 62.8 ± 22.7 65.4 ± 22.3 47.5 ± 19.1 0.001
eGFR < 60 mL/min 176 (48.1%) 139 (44.4%) 37 (69.8%) 0.001
Procedural characteristics
AKI post CT diagnostics 22 (6.7%) 13 (4.7%) 9 (17.3%) 0.003
PCI 177 (46.0%) 144 (46.0%) 33 (62.3%) 0.029
CT TAVI in different stays 112 (30.6%) 97 (31%) 15 (28.3%) 0.694
Coronary angiography on TAVI day 125 (23.2%) 100 (31.9%) 25 (47.2%) 0.031
Contrast agent TAVI [mL] 222.7 ± 88.1 219.9 ± 86.5 244.2 ± 95.3 0.055
General anaesthesia 86 (23.5%) 68 (21.7%) 18 (34%) 0.052
CRP max [mg/dL] 61.7 ± 60.3 54.3 ± 53.5 105.2 ± 77.8 0.001
Renal replacement therapy after TAVI 3 (0.8%) 0 (0%) 3 (5.7%) 0.003
Mortality 8 (2.2%) 3 (1%) 5 (9.4%) 0.002
Hospital stay [days] 13.9 ± 7.1 12.8 ± 5.7 20.4 ± 10.8 0.001
ICU stay [days] 2.7 ± 2.3 2.5 ± 2.2 3.4 ± 2.7 0.010
Pacemaker implantation necessary 83 (22.7%) 64 (20.4%) 19 (35.8%) 0.013
Data are given as mean ± standard deviation or number of patients (percent of all patients in group). ACEI — angiotensin converting enzyme 
inhibitor; AV — aortic valve; CCS — Canadian Cardiovascular Society; CRP — C-reactive protein; CT — computed tomography; eGFR — esti-
mated glomerular filtration ratio; ICU — intensive care unit; NYHA — New York Heart Association; PCI — percutaneous coronary intervention; 
STS-Score — Society of Thoracic Surgeons — Score for mortality
4 www.cardiologyjournal.org
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Figure 1. Kidney function during pre-procedural planning, transcatheter aortic valve implantation (TAVI) and after 
TAVI. Differences to baseline-creatinine (A) and estimated glomerular filtration ratio (eGFR; mL/min) (B) are shown 
in all patients and patients with and without pre-existing chronic kidney disease. Creatinine differences are shown in 
patients developing an acute kidney injury (AKI) after TAVI (C). Data are given as mean ± standard error of the mean; 
CT — computed tomography.
binary logistic regression analysis, whereas base-
line creatinine showed a positive trend (OR 2.13 
[0.92–4.90], p = 0.076) (Suppl. Fig. 2). 
Risk factors for AKI after TAVI
The TAVI procedure itself may worsen re-
nal function due to hemodynamic impairment or 
contrast agent. After TAVI, 53 patients suffered 
from AKI (14.5%): 44 had KDIGO stage I (83% of 
patients with AKI), 6 (11%) had KDIGO stage II 
and 3 (5%) had KDIGO stage III and needed RRT. 
Patients with AKI were older, had higher creatinine 
levels and more often CKD stage ≥ III. Mortality 
was higher in patients with AKI (9.4% vs. 1.0%, 
p = 0.002; Table 1). 
Univariate (Suppl. Table 1) and multivariate 
binary logistic regression analysis to identify in-
dependent predictors of AKI after TAVI were per-
formed. Independent predictors of AKI post TAVI 
were arterial hypertension, baseline-creatinine 
and coronary intervention during pre-procedural 
diagnostics. Patients with AKI after CT showed 
higher risk for AKI after TAVI as well (Fig. 2).
Incidence and risk factors for renal  
impairment at discharge
Testing the hypothesis that renal function 
could recover, creatinine levels were analyzed 
during follow up by creating three groups with dif-
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group with improved kidney function (creatinine < 
< 0.8 times baseline), one group with stable kidney 
function (creatinine 0.8–1.2 times baseline) and one 
group with impaired kidney function (creatinine > 
> 1.2 times baseline). The group with impairment 
of kidney function was further divided into moder-
ate and severe impairment (moderate: creatinine 
1.2–1.5 times baseline; severe: creatinine > 1.5 
times baseline or RRT). Most patients had stable or 
improved kidney function independent of the CKD 
stage (89.5% in CKD ≤ II, 92.6% in CKD stage ≥ III). 
While 33 (9%) patients had impaired kidney func-
tion at discharge, only 8 (2.1%) patients showed 
severe impairment of kidney function (Fig. 3A). 
In patients with CKD stage ≥ III, impairment of 
kidney function did not occur more often than in 
patients with CKD stage ≤ II (7.4% vs. 10.5%, 
p = 0.295). Patients with CKD stage ≥ III showed 
higher rates of improved kidney function (22.7% 
vs. 5.8%, p < 0.001). 
Univariate (Suppl. Table 2) and multivari-
ate binary logistic regression was performed to 
identify independent predictors of impaired kidney 
function after TAVI. Multivariate logistic regres-
sion showed that baseline-creatinine is no predictor 
of impaired kidney function after TAVI. Higher 
baseline creatinine rather negatively correlates 
to impaired kidney function. In contrast, AKI post 
Figure 3. Long-time renal impairment. Patients were divided in four groups with different changes in renal function: 
One group with improved renal function (creatinine < 0.8 times baseline), one group with stable renal function (cre-
atinine 0.8–1.2 times baseline), one group with moderately impaired renal function (creatinine 1.2–1.5 times baseline) 
and one group with severely impaired renal function (creatinine > 1.5 times baseline or renal replacement therapy); 
A. The proportion of patients at discharge; B. The proportion at follow-up (161 ± 87 days); CKD — chronic kidney 
disease.
Figure 2. Multivariate analysis of risk factors for acute kidney injury (AKI) after transcatheter aortic valve implantation 
(TAVI). Predictors of impaired kidney function after TAVI. Figure shows multivariate logistic regression analysis with 
odds ratio (OR) (95% confidence interval) of different predictors for AKI after TAVI. OR > 1 marks positive predictors, 































TAVI, C-reactive protein (CRP, mg/dL) and grade 
of mitral valve insufficiency before TAVI were 
positive predictors (Fig. 4).
Incidence and risk factors for renal  
impairment at follow up
At follow up, 19.1% of all patients had impaired 
renal function, including 3.4% patients with se-
vere impaired kidney function with no differences 
concerning CKD stage (Fig. 3B). Improvement of 
kidney function occurred more often in patients 
with CKD stage ≥ III (p < 0.001).
Discussion
Renal function during the complete TAVI work-
flow including pre-procedural diagnostics, TAVI 
itself, renal function at discharge and at postinter-
ventional follow up were analyzed. We were able to 
demonstrate several points: First, we showed that 
AKI after CT for TAVI evaluation is rare and leads 
only to moderate stages of AKI. Second, we showed 
that renal function after AKI recovers almost fully 
in most cases. Third, we demonstrated that patients 
with CKD showed no higher rates of short- and long-
term impairment, but higher rates of improvement 
of renal function after TAVI.
AKI post CT
There is only little data concerning AKI after 
intravenous contrast agent injection for CT in pa-
tients with severe aortic stenosis. Jochheim et al. 
[12] showed an incidence of AKI of 10.5%. Risk for 
AKI was increased only in patients with impaired 
baseline renal function who received volumes 
> 90 mL [12]. The incidence we demonstrated is 
lower (6.7%) and is in the range of recently pub-
lished studies on patients undergoing CT for other 
reasons (~6.4%) [14]. We were not able to identify 
patients with an increased risk for AKI, although 
baseline creatinine showed a positive trend. Ad-
ditionally, no correlation to the amount of injected 
contrast agent was seen, which agrees with the data 
of a meta-analysis using propensity score matching, 
which showed no difference in rates of AKI, RRT 
and mortality between patients receiving iodinated 
intravenous contrast agent and those receiving 
no contrast agent [15]. Most importantly, shown 
herein, is that the stage of AKI is low and no RRT 
was needed after CT. Furthermore, AKI after CT 
is no independent predictor for impaired kidney 
function after TAVI. Since mortality of severe aor-
tic valve stenosis is high, a CT for planning TAVI 
should not be generally rejected due to concerns 
of renal impairment.
AKI post TAVI
Acute kidney injury is a frequent complication 
after TAVI due to impaired hemodynamics dur-
ing implantation and the use of a contrast agent. 
Incidence ranges from 8.3% to 58% [16]. This 
high range might partly be explained by different 
study populations and different definitions of AKI. 
A multicenter study showed an incidence of 20.7% 
Figure 4. Mulitvariate analysis of risk factors for short term renal function. This figure shows multivariate logistic re-
gression analysis with odds ratio (OR) (95% confidence interval) of different predictors for impaired short-term renal 
function after transcatheter aortic valve implantation (TAVI). OR > 1 marks positive predictors, OR < 1 marks negative 
predictors; AKI — acute kidney injury; CRP — C-reactive protein; CT — computed tomography; STS-Score — Society 
of Thoracic Surgeons — Score for mortality.
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with a reduced incidence at increasing stages 
(stage I: 15%: stage II or III: 6%) [17]. By using 
the updated Valve Academic Research Consortium 
(VARC)-2 criteria, recommending that the timing 
for the diagnosis of AKI should be 7 days [18], we 
report an incidence of AKI of 14.5% with very low 
incidences of higher stages (stage II or III: 2.5%) 
and high rates of stage I (12.0%), which are not 
associated with an increased 1-year mortality ac-
cording to previous studies [19]. 
Studies analyzing risk factors for AKI post 
TAVI are heterogenous. Referring to preexist-
ing CKD, there are publications proposing an 
association with baseline-creatinine levels and 
AKI post TAVI [5–7, 9], while others did not find 
any association between patients with or without 
CKD [8]. In the present analysis, a high correla-
tion of baseline-creatinine and AKI post TAVI was 
reported. AKI post CT was also identified as an 
independent predictor of AKI post TAVI. According 
to available research, this study is the first to report 
this correlation. However, at follow-up patients 
suffering from AKI during TAVI workflow showed 
only slightly impaired levels.
Renal function after TAVI
Although there is a lot of data on AKI after 
TAVI, less is known about the effect of the treat-
ment of aortic valve stenosis on short- and long- 
-term kidney function for the entire TAVI pack-
age, including pre-procedural diagnostics and the 
procedure itself. Herein, was hypothesized that 
better perfusion after TAVI could improve the renal 
function and compensate for negative effects such 
as contrast agent application, rapid pacing or intra-
operative hypotension during TAVI. Indeed, there 
was an improvement in short-term renal function of 
13.9%, while observing an impaired renal function 
in only 9% of all patients. Also, relevant impairment 
of renal function (2.1%, including patients with 
RRT) or necessity of RRT (0.8%) were very low. 
Interestingly, the presence or absence of higher 
stages of CKD were no predictors of impaired re-
nal function, which did not worsen more often in 
patients with higher CKD stages. On the contrary, 
a negative correlation of short-term impairment 
of kidney function and baseline-creatinine was 
noted. This is concordant with a recent publication 
reporting improved renal function 1 year after TAVI 
for patients with moderate-to-severe CKD [20]. 
Others have found similar results, with 1 recent 
study showing in a logistic regression analysis that 
lower baseline renal function was predictive for 
improved renal function after TAVI [7]. Although 
the study included more than 1,500 patients, the 
definition of improved renal function used, defined 
as a positive change 48 hours after TAVI, was very 
short-termed. Nevertheless, ratios of improved 
short-term kidney function in the CKD group 
were similar to the present ones. Consequently, 
the findings herein, support the findings of these 
publications. 
Interestingly, higher CRP-levels were also 
associated with impaired kidney function at dis-
charge. It was assumed that this was related to an 
increased rate of kidney failure in the context of 
potential infections or also possibly to the use of ne-
phrotoxic antibiotics. Consequently, an appropriate 
effort should be made to avoid postinterventional 
infections. 
Referring to the higher ratios of impaired 
kidney function at follow up, a correlation to TAVI 
is not assumed, since the impairing effect of TAVI 
(i.e., complications) should naturally occur before 
discharge. We rather propose the natural impair-
ment of kidney function in our aged patient cohort.
Due to the small number of patients with 
renal replacement therapy after TAVI (0.8%), the 
impact of CKD could not be analyzed. Data in the 
United Kingdom TAVI Registry showed that the 
risk of new dialysis requirement after TAVI was 
independently associated with lower baseline kid-
ney function [21]. Nevertheless the present study 
shows that concerns of impairing kidney function 
in CKD patients after TAVI should not be grounds 
for refusal of TAVI. 
Limitations of the study
When discussing the results presented in 
the present analysis, some limitations have to be 
considered. This is single-center retrospective 
data and results have to be considered hypothesis-
generating, and should be confirmed in larger 
multi-center trials. 
In clinical routine, commonly there is a great 
diversity in the diagnostic sequence. Sometimes 
a patient undergoes CT, coronary angiography and 
PCI before TAVI in the same stay, whereas in the case 
of staged procedures, there could be no exposition 
with contrast agent prior to TAVI. The distribution of 
these patients could have impacted the homogeneity 
of the study population. Due to the study setting, 
measurement of creatinine levels was at the discre-
tion of the treating physician and not performed daily. 
Consequently, an underreported incidence or an un-
derestimated stage of AKI cannot be excluded. Since 
the last measured creatinine was analyzed before 
discharge, the rate of impaired kidney function may 
8 www.cardiologyjournal.org
Cardiology Journal
be overestimated, since creatinine after AKI could 
further decrease. We can rule out an underestima-
tion, since patients with increasing creatinine are not 
discharged in our hospital. Additionally, the cohort 
of patients was reduced at follow up, complicating 
interpretation of the follow up analysis.
Clinical data was based on medical reports. 
Since structured clinical interviews were not used, 
some variables are likely to be underreported.
Conclusions
The present study suggests that relevant 
impairment of renal function after TAVI is rare, 
and occurs independently of reduced renal func-
tion. Additionally, the data suggests that TAVI 
can improve renal function in patients with CKD. 
This is clinically important, since it could help 
facilitate decision-making for the TAVI interven-
tion, and improve the risk assessment in these 
patients. Furthermore, it was demonstrated that 
CT in pre-procedural diagnostics does not impair 
renal function. 
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